A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial conducted in the first half of 2021 and co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.
Large International Trial Shows Strong Protection Against Severe COVID-19 with Antibody Combination miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial conducted in the first half of 2021 and co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.
Zhongshan health authorities in South China’s Guangdong Province recently reported a case of a human infected with an avian influenza A (H3N8) virus, with the infected individual also suffering from multiple myeloma and other underlying medical conditions. An expert told the Global Times on Wednesday that the case is “an individual case,” and the risk of spread is low.